The Food and Drug Administration recently approved Eli Lilly’s obesity drug Zepbound, also known as tirzepatide, as the first treatment for obstructive sleep apnea (OSA) in the United States. This approval marks a significant milestone as it is the first time Zepbound has been cleared for a condition other than weight loss.
Obstructive sleep apnea is a common sleep disorder characterized by breathing interruptions during sleep. It can have serious health consequences if left untreated, including increased risk of heart disease, stroke, and other complications. Patients with both obesity and moderate-to-severe OSA can now benefit from Zepbound as a targeted treatment option.
The approval of Zepbound for OSA could lead to broader insurance coverage, making it more accessible to patients in need. This development highlights the potential of repurposing existing drugs for new indications, expanding their utility and impact in healthcare.
